Alrizomadlin

N/A

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NameAlrizomadlin
Drug Alias NameAPG-115AA-115
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp53-binding protein Mdm-2 inhibitorsTumor protein p53 stimulants
Targetsp53-binding protein Mdm-2Tumor protein p53
Therapy Area/IndicationsUveal melanomaSkin MelanomaSolid tumours +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Ascentage Pharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChildren'S National Research InstituteAscentage Pharma Group IncUniversity Of Michigan Rogel Cancer Center +[4] 
Inactive CompaniesNational Cancer Institute
Active IndicationsUveal melanomaSkin MelanomaSolid tumours +[17] 
Inactive IndicationsHematologic NeoplasmsMesotheliomaLymphoma

Other Information

ATC CodeN/A
Related LinksN/A